PL2328893T3 - Związki triazolowe modulujące aktywność Hsp90 - Google Patents
Związki triazolowe modulujące aktywność Hsp90Info
- Publication number
- PL2328893T3 PL2328893T3 PL09791292T PL09791292T PL2328893T3 PL 2328893 T3 PL2328893 T3 PL 2328893T3 PL 09791292 T PL09791292 T PL 09791292T PL 09791292 T PL09791292 T PL 09791292T PL 2328893 T3 PL2328893 T3 PL 2328893T3
- Authority
- PL
- Poland
- Prior art keywords
- triazole compounds
- hsp90 activity
- modulate hsp90
- modulate
- activity
- Prior art date
Links
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- -1 Triazole compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18839708P | 2008-08-08 | 2008-08-08 | |
| EP20090791292 EP2328893B1 (en) | 2008-08-08 | 2009-08-07 | Triazole compounds that modulate hsp90 activity |
| PCT/US2009/053157 WO2010017479A1 (en) | 2008-08-08 | 2009-08-07 | Triazole compounds that modulate hsp90 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2328893T3 true PL2328893T3 (pl) | 2013-09-30 |
Family
ID=41172462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09791292T PL2328893T3 (pl) | 2008-08-08 | 2009-08-07 | Związki triazolowe modulujące aktywność Hsp90 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9126953B2 (pl) |
| EP (1) | EP2328893B1 (pl) |
| DK (1) | DK2328893T3 (pl) |
| ES (1) | ES2415234T3 (pl) |
| PL (1) | PL2328893T3 (pl) |
| PT (1) | PT2328893E (pl) |
| WO (1) | WO2010017479A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006279794B2 (en) | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US8318790B2 (en) | 2006-05-25 | 2012-11-27 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| US20080027047A1 (en) * | 2006-05-25 | 2008-01-31 | Weiwen Ying | Compounds that modulate HSP90 activity and methods for identifying same |
| WO2007139951A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2026797A2 (en) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| WO2007147265A1 (en) | 2006-06-23 | 2007-12-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| WO2008097640A2 (en) | 2007-02-08 | 2008-08-14 | Synta Pharmaceuticals Corp. | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| CA3050455A1 (en) | 2008-11-03 | 2010-06-03 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| ME02144B (me) | 2010-12-20 | 2015-10-20 | Sigma Tau Res Switzerland Sa | Jedinjenja aril triazola sa antitumorskom aktivnošću |
| SI3173427T1 (sl) | 2011-03-31 | 2019-08-30 | ADC Therapeutics SA, | Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega |
| WO2013006864A2 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| CN102391260B (zh) * | 2011-09-29 | 2014-12-10 | 上海交通大学 | 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途 |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| IN2014CN04690A (pl) | 2012-01-09 | 2015-09-18 | Alethia Biotherapeutics Inc | |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| CN104447658A (zh) * | 2014-12-04 | 2015-03-25 | 杭州杜易科技有限公司 | 一种卤代4-色满酮衍生物的制备方法 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| US11724997B2 (en) | 2018-03-01 | 2023-08-15 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01498B (me) * | 2004-11-18 | 2014-04-20 | Synta Pharmaceuticals Corp | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| AU2006279794B2 (en) * | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| TWI446910B (zh) * | 2005-08-18 | 2014-08-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性的三唑化合物 |
| EP1951679B1 (en) * | 2005-08-18 | 2015-02-18 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
| TW200806637A (en) * | 2006-05-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Synthesis of triazole compounds that modulate HSP90 activity |
| EP2038262B1 (en) * | 2006-05-25 | 2014-11-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2007139951A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| EP2026797A2 (en) * | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| US8318790B2 (en) * | 2006-05-25 | 2012-11-27 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| US20080027047A1 (en) * | 2006-05-25 | 2008-01-31 | Weiwen Ying | Compounds that modulate HSP90 activity and methods for identifying same |
| CA2653329C (en) * | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2054059A2 (en) * | 2006-08-17 | 2009-05-06 | Synta Pharmaceuticals Corporation | Triazole compounds that modulate hsp90 activity |
| US20110046125A1 (en) * | 2006-10-19 | 2011-02-24 | Synta Pharmaceuticals Corp. | Method for treating infections |
| US20100280032A1 (en) * | 2006-10-26 | 2010-11-04 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| WO2008097640A2 (en) * | 2007-02-08 | 2008-08-14 | Synta Pharmaceuticals Corp. | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
| US8993608B2 (en) * | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| CA2682665C (en) * | 2007-03-27 | 2015-07-21 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
| US8648104B2 (en) * | 2007-05-25 | 2014-02-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-Met |
| EP2193135A1 (en) * | 2007-08-13 | 2010-06-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| WO2009148599A1 (en) * | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| WO2009158026A1 (en) * | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| TW201011003A (en) * | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| NZ622713A (en) * | 2009-10-19 | 2015-07-31 | Synta Pharmaceuticals Corp | Combination cancer therapy with hsp90 inhibitory compounds |
| WO2011133521A2 (en) * | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| US9205086B2 (en) * | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| WO2011146801A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| EP2575810A1 (en) * | 2010-05-24 | 2013-04-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| WO2012026931A1 (en) * | 2010-08-25 | 2012-03-01 | Synta Pharmaceuticals Corp. | Method of synthesizing substituted 2-alkyl phenols |
| CA2810254A1 (en) * | 2010-09-13 | 2012-03-22 | Vojo Vukovic | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| US20140005145A1 (en) * | 2010-12-08 | 2014-01-02 | Synta Pharmaceuticals Corp. | Combination breast cancer therapy with hsp90 inhibitory compounds |
| WO2012096919A1 (en) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| WO2012116061A1 (en) * | 2011-02-23 | 2012-08-30 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| CN103391779A (zh) * | 2011-02-24 | 2013-11-13 | 辛塔医药品有限公司 | 使用hsp90抑制性化合物的前列腺癌治疗 |
| US20140045908A1 (en) * | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| US8628752B2 (en) * | 2011-10-28 | 2014-01-14 | Synta Pharmaceuticals Corp. | Methods of identifying HSP90 inhibitors with less ocular toxicity |
-
2009
- 2009-08-07 PT PT97912927T patent/PT2328893E/pt unknown
- 2009-08-07 US US13/057,962 patent/US9126953B2/en active Active
- 2009-08-07 WO PCT/US2009/053157 patent/WO2010017479A1/en not_active Ceased
- 2009-08-07 PL PL09791292T patent/PL2328893T3/pl unknown
- 2009-08-07 DK DK09791292T patent/DK2328893T3/da active
- 2009-08-07 EP EP20090791292 patent/EP2328893B1/en active Active
- 2009-08-07 ES ES09791292T patent/ES2415234T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2328893E (pt) | 2013-06-27 |
| US9126953B2 (en) | 2015-09-08 |
| EP2328893B1 (en) | 2013-03-20 |
| WO2010017479A1 (en) | 2010-02-11 |
| ES2415234T3 (es) | 2013-07-24 |
| DK2328893T3 (da) | 2013-06-17 |
| US20110224206A1 (en) | 2011-09-15 |
| EP2328893A1 (en) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2328893T3 (pl) | Związki triazolowe modulujące aktywność Hsp90 | |
| ZA201001064B (en) | Triazole compounds that modulate Hsp90 activity | |
| IL200241A0 (en) | Triazole compounds that modulate hsp90 activity | |
| PL2035396T3 (pl) | Związki triazolowe modulujące aktywność hsp90 | |
| EP2141990A4 (en) | ACTIVE COMPOUNDS ON 11BETA-HSD1 | |
| GB2463078B (en) | Distributed storage | |
| IL207757A0 (en) | Hererocyclic compound | |
| ZA201101410B (en) | Insecticidal compounds | |
| ZA201100804B (en) | Insecticidal compounds | |
| IL210226A0 (en) | Azole compound | |
| IL200165A0 (en) | Compounds that inhibit cholinesterase | |
| ZA201100032B (en) | Triazole derivative or salt thereof | |
| IL211628A0 (en) | Insect loading system | |
| GB0813042D0 (en) | Insecticidal compounds | |
| GB0801811D0 (en) | Secure partitioning | |
| HK1144820A (en) | Triazole compounds that modulate hsp90 activity | |
| GB0819323D0 (en) | Insecticidal compounds | |
| GB0819791D0 (en) | Insecticidal compounds | |
| GB0823484D0 (en) | Insecticidal compounds | |
| GB0813849D0 (en) | Insecticidal compounds | |
| GB0816133D0 (en) | Insecticidal compounds | |
| GB0819790D0 (en) | Insecticidal compounds | |
| PL385082A1 (pl) | Układ konserwujący do kosmetyków | |
| HK1121154A (en) | Imidazole compounds that modulate hsp90 activity | |
| GB0801596D0 (en) | Compounds |